Evidence map›Paper›PMID 28636653›Full record

ArticlePloS one2017

The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.

Kari A Dilley, Alexander A Voorhies, Priya Luthra, Vinita Puri, Timothy B Stockwell, Hernan Lorenzi, Christopher F Basler, Reed S Shabman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Viral Infections in Pregnancy: A Focus on Ebola Virus.Current pharmaceutical design · 2018
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kari A DilleyVirology Group, J. Craig Venter Institute, Rockville, Maryland, United States of America.ORCID http://orcid.org/0000-0001-7771-2901
Alexander A VoorhiesInfectious Disease Group, J. Craig Venter Institute, Rockville, Maryland, United States of America.
Priya LuthraCenter for Microbial Pathogenesis, Georgia State University, Atlanta, Georgia, United States of America.
Vinita PuriVirology Group, J. Craig Venter Institute, Rockville, Maryland, United States of America.
Timothy B StockwellVirology Group, J. Craig Venter Institute, Rockville, Maryland, United States of America.
Hernan LorenziInfectious Disease Group, J. Craig Venter Institute, Rockville, Maryland, United States of America.
Christopher F BaslerCenter for Microbial Pathogenesis, Georgia State University, Atlanta, Georgia, United States of America.
Reed S ShabmanVirology Group, J. Craig Venter Institute, Rockville, Maryland, United States of America.
J. Craig Venter Institute · USGeorgia State University · US

Funding

The J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI SUTTON, GRANGER GIDEON · 2014 to 2018
$29.7M
Molecular mechanisms of immune dysregulation by filoviral interferon U19AI109945 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$9.5M
NIAID NIH HHS U19 AI109945NIAID NIH HHS U19 AI110819
6 · The paper itself

Abstract

Ebola virus and Marburg virus are members of the Filovirdae family and causative agents of hemorrhagic fever with high fatality rates in humans. Filovirus virulence is partially attributed to the VP35 protein, a well-characterized inhibitor of the RIG-I-like receptor pathway that triggers the antiviral interferon (IFN) response. Prior work demonstrates the ability of VP35 to block potent RIG-I activators, such as Sendai virus (SeV), and this IFN-antagonist activity is directly correlated with its ability to bind RNA. Several structural studies demonstrate that VP35 binds short synthetic dsRNAs; yet, there are no data that identify viral immunostimulatory RNAs (isRNA) or host RNAs bound to VP35 in cells. Utilizing a SeV infection model, we demonstrate that both viral isRNA and host RNAs are bound to Ebola and Marburg VP35s in cells. By deep sequencing the purified VP35-bound RNA, we identified the SeV copy-back defective interfering (DI) RNA, previously identified as a robust RIG-I activator, as the isRNA bound by multiple filovirus VP35 proteins, including the VP35 protein from the West African outbreak strain (Makona EBOV). Moreover, RNAs isolated from a VP35 RNA-binding mutant were not immunostimulatory and did not include the SeV DI RNA. Strikingly, an analysis of host RNAs bound by wild-type, but not mutant, VP35 revealed that select host RNAs are preferentially bound by VP35 in cell culture. Taken together, these data support a model in which VP35 sequesters isRNA in virus-infected cells to avert RIG-I like receptor (RLR) activation.

Indexed as

EbolavirusHemorrhagic Fever, EbolaHigh-Throughput Nucleotide SequencingHost-Pathogen InteractionsHumansInterferonsRNA, Double-StrandedSendai virusSignal TransductionViral Regulatory and Accessory ProteinsInterferonsRNA, Double-StrandedViral Regulatory and Accessory ProteinsVP35 protein, filovirus

Identifiers

PMID28636653
PMCPMC5479518
OpenAlexW2652825108

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.